Vytrus Biotech reinforces its production capacity with a 3.5 million euro investment in a new plant in Terrassa. This expansion project is designed to meet the growing demand for its natural active ingredients in the cosmetics sector.
Vytrus Biotech, specialized in active ingredients derived from plant biotechnology for the cosmetics industry, has announced a strategic investment to create a new production plant in Terrassa, Spain. Scheduled to take place between 2025 and 2026, the 3.5 million euro initiative will strengthen the company's industrial structure with a 1,600 m² plant, while meeting the growing international demand for natural ingredients for cosmetics.
International expansion and growth
In this first phase of expansion, Vytrus plans to triple its production capacity to meet the growing expectations of its international customers. This initiative is in line with the company's growth strategy, which aims to consolidate its position as an international reference in biotechnology applied to cosmetics. The company is also focusing on innovation and sustainability to generate value for its shareholders and customers.
The financing of this expansion is based on a balanced structure, with 50 % from own resources and 50 % from long-term bank financing, thus ensuring a prudent financial profile.
Against a backdrop of strong growth, Vytrus Biotech recorded a 75 % increase in sales in the first half of 2025 compared with 2024, with sales of 4.38 million euros. This performance was driven by rigorous cost management and a marked increase in its international presence in several regions, notably Asia-Pacific, where sales were strong.
Finally, thanks to this investment and development strategy, Vytrus expects to achieve sales of 12 million euros and EBITDA of 5 million euros by 2027, in line with its strategic plan.
